Diseases / Fatty Liver
Fatty Liver
DiseaseFatty liver disease, also called hepatic steatosis, is a condition characterized by excess fat accumulation in liver tissue. Many patients are asymptomatic, but disease can progress to steatohepatitis, fibrosis, cirrhosis, and liver cancer in a subset of individuals. Major risk factors include obesity, diabetes, and alcohol use.
- Trials
- 589
- Recruiting
- 80
- Completed
- 306
- With results
- 76
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | 5 | — | 1 | — | 1 | 7 |
| Phase 1 | 5 | — | — | — | 10 | 6 | 2 | — | 1 | 24 |
| Phase 1/2 | 5 | — | — | 1 | 8 | 2 | — | — | 1 | 17 |
| Phase 2 | 9 | 1 | — | 3 | 43 | 8 | 2 | — | 4 | 70 |
| Phase 2/3 | — | 1 | — | — | 3 | — | — | — | 2 | 6 |
| Phase 3 | 6 | 1 | — | — | 9 | 3 | 2 | — | 3 | 24 |
| Phase 4 | 3 | 1 | 1 | — | 21 | 3 | 1 | — | 6 | 36 |
| Not applicable | 24 | 10 | 5 | 3 | 130 | 7 | 9 | — | 32 | 220 |
| Unknown | 28 | 14 | 2 | 6 | 77 | 3 | 4 | 1 | 50 | 185 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Fatty Liver | 7 | 24 | 17 | 70 | 6 | 24 | 36 | 220 | 185 | 589 |
| Non-alcoholic Fatty Liver Disease | 3 | 9 | 10 | 51 | 3 | 17 | 14 | 88 | 64 | 259 |
| Obesity | 2 | 6 | 4 | 8 | 1 | 2 | 5 | 40 | 34 | 102 |
| Liver Cirrhosis | — | 1 | 5 | 4 | — | 1 | 3 | 19 | 39 | 72 |
| Insulin Resistance | — | 1 | 1 | 13 | — | 1 | 5 | 28 | 10 | 59 |
| Metabolic Syndrome | — | 1 | 1 | 2 | — | 1 | 5 | 22 | 18 | 50 |
| Liver Diseases | — | 1 | 4 | 11 | — | 4 | 4 | 12 | 13 | 49 |
| Diabetes Mellitus, Type 2 | 1 | 4 | 2 | 6 | — | 1 | 13 | 13 | 8 | 48 |
| Fibrosis | — | 1 | 3 | 10 | — | 7 | — | 5 | 21 | 47 |
| Diabetes Mellitus | — | 2 | 1 | 11 | — | 2 | 6 | 11 | 11 | 44 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 13 | 2 |
| 2 | Assiut University | 9 | 1 |
| 3 | Seoul National University Hospital | 7 | 0 |
| 4 | Cairo University | 6 | 0 |
| 5 | Massachusetts General Hospital | 6 | 0 |
| 6 | Tehran University of Medical Sciences | 6 | 0 |
| 7 | University of Colorado, Denver | 6 | 2 |
| 8 | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 0 |
| 9 | University of Oxford | 5 | 0 |
| 10 | University of Texas Southwestern Medical Center | 5 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Exercise | 15 |
| 2 | Vitamin E | 13 |
| 3 | Pioglitazone | 12 |
| 4 | Diet | 11 |
| 5 | Metformin | 8 |
| 6 | Ultrasonography | 8 |
| 7 | Diet Therapy | 7 |
| 8 | empagliflozin | 7 |
| 9 | Caloric Restriction | 6 |
| 10 | Diet, Fat-Restricted | 6 |
Evidence
- Results reported
- 24.8%76 of 306 completed
- Published
- 13.4%41 of 306 completed
- Primary endpoint met
- 50.8%32 of 63 analyses
- Median months to report
- 16
Documents disclosed
Trial profile
- Median enrollment
- 65
- Median duration
- 26.8months
- Countries
- 58
- Study sites
- 2616
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 31
- Phase 1
- 32
- Phase 1/2
- 44
- Phase 2
- 60
- Phase 2/3
- 75
- Phase 3
- 100
- Phase 4
- 50
- Not applicable
- 50
- Unknown
- 138
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | San Antonio | United States | 35 |
| 2 | Dallas | United States | 24 |
| 3 | London | United Kingdom | 23 |
| 4 | Houston | United States | 22 |
| 5 | Los Angeles | United States | 22 |
| 6 | New York | United States | 21 |
| 7 | Paris | France | 21 |
| 8 | Miami | United States | 20 |
| 9 | Richmond | United States | 20 |
| 10 | Boston | United States | 19 |
Terminations
- Terminated
- 32
- Withdrawn
- 21
- Suspended
- 1
- Stopped for recruitment
- 1.4%8 of 589 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06594523 Withdrawn | Withdrawn | Business decision | 2030-12-31 |
| NCT04160949 Withdrawn | Withdrawn | Company focus shifted | 2030-07-31 |
| NCT01148550 Suspended | Suspended | 2029-05-31 | |
| NCT06692283 Withdrawn | Withdrawn | Business decision | 2027-06-30 |
| NCT03542578 Terminated | Terminated | Changes in the study staff's role and clinic commitments | 2026-07-09 |
| NCT04302051 Withdrawn | Withdrawn | The sponsor withdrew from the study | 2026-07-09 |
| NCT05769127 Withdrawn | Withdrawn | funding withdrawn | 2025-06-10 |
| NCT03914482 Withdrawn | Withdrawn | The qualified and Principal Investigator has moved institutes. We are in the process for finding a replacement. | 2024-12-30 |
| NCT07052682 Terminated | Terminated | Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda. | 2024-12-30 |
| NCT05864391 Terminated | Terminated | AstraZeneca have decided to not move forward with the development of the compound. | 2024-03-20 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: